Article
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Antiviral therapy - 1 Jan 2011
Pulido Federico, Arribas José R, Hill Andrew, Van Delft Yvon, Moecklinghoff Christiane
Abstract excerpt
BACKGROUND: When patients have HIV RNA suppressed to <50 copies/ml on current treatment, switching to darunavir (DRV)/ritonavir (DRV/r) monotherapy could prevent the development of resistance to other drug classes. METHODS: In the MONET trial, 256 patients with HIV RNA<50 copies/ml on current highly active antiretroviral therapy (57% with protease inhibitors [PIs] and 43% with non-nucleoside reverse transcriptase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.